Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...
Sage Therapeutics, Inc. SAGE reported a loss of $1.56 per share for the fourth quarter of 2024, wider than the Zacks ...
Biogen currently co-markets Sage’s postpartum depression (PPD) drug Zurzuvae (zuranolone). Despite rejecting the offer, Sage’s board has stated it will consider “strategic alternatives” to ...
Biogen and Sage co-developed Zurzuvae, which was approved by the FDA for PPD in August 2023. Sage has experienced several setbacks since this approval. Zurzuvae did not win approval as a treatment ...
Sage Therapeutics has said it will cut its headcount by 40% in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the FDA, with two of the company's founders ...
While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...
Sage is focused on the goal of establishing ZURZUVAE as the standard of care for women with postpartum depression (PPD). The current commercialization investment plan includes joint sales force ...
In the fourth quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.
Reports Q4 revenue $12.8M, consensus $14.4M. “We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is ...
Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of shareholders.
“We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is being recognized as an important treatment option for women with postpartum depression and we ...